Records from about 4,900 German practices show over half of patients stayed below 10 mg in their first six months, with 5 mg the most common dose.
Recap by typeshit. Full story at BIOENGINEER.
The review looks at concerns about misuse as demand for GLP-1 drugs grows, and points to how little evidence guides their use beyond approved conditions.
Researchers found self-reported GLP-1 use climbed from March 2024 to October 2025, mostly for weight loss, through channels insurance data may not capture.
The study is looking for women with hot flashes and night sweats and a BMI above 30. Mayo Clinic has the full eligibility rules and how to sign up.
A matched cohort study in Inflammatory Bowel Diseases found remission odds nearly six times higher on GLP-1 drugs, and weight loss alone didn't explain it.
A comment-for-link Instagram post saying trials of semaglutide, tirzepatide and retatrutide showed up to 28% weight loss. Little detail beyond that.
The EMA's CHMP amended its type 2 diabetes indication, and Italian diabetologists say Italy could be the first European country to offer the once-weekly combo.
Loading…